Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.

ABSTRACT:

Objective

This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects.

Methods

We systematically searched Embase, MEDLINE, and Cochrane for phase 3 and 4 randomized controlled trials (RCTs) with a minimum duration of 40 weeks. Included studies compared GLP-1 RAs to placebo or to each other in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²), with or without type 2 diabetes (T2DM). We excluded crossover trials, open-label studies, early-phase trials, and studies focusing on specific subpopulations.

Results

A total of 22 RCTs involving 41,757 participants were included. Amon

SUBMITTER: Velji-Ibrahim J 

PROVIDER: S-EPMC12591819 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature